DIL Dyadic International

Dyadic International, Inc. (AMEX:DIL), a biotechnology company, announced today that it was granted U.S. patent 7,122,330, "High-Throughput Screening of Expressed DNA Libraries in Filamentous Fungi," by the U.S. Patent and Trademark Office. Dr. Glenn Nedwin, Dyadic's Chief Scientific Officer, Executive Vice President and President of Dyadic's Biosciences Business, said, "This patent protects Dyadic's novel technology for robotic screening in filamentous fungi using our proprietary C1 Host Technology platform. With broad claims covering a number of other industrially relevant fungi, including Trichoderma and Aspergillus, we believe the patent also validates Dyadic's 'one stop shop' model where gene discovery and improvement, gene expression, and product manufacturing in quantities from 1 ml to 150,000 liters can all be performed in the same host organism. We believe that this, in turn, should improve the odds of identifying potentially useful proteins, shorten R&D development timelines, and reduce development costs." Dr. Nedwin added, "We already are using this patented technology in Dyadic's programs to identify optimal enzymes and enzyme mixtures to increase the efficiency of extracting sugars from renewable biomass, a critical step in the production of low-cost cellulosic ethanol, plastics, polymers and other products now derived from petroleum. We also are using our technology to expand the pipeline of new, more effective and lower cost enzymes used in the pulp & paper, textile, animal feed and other industrial processes, and are developing the technology to facilitate the rapid, low-cost screening of antibodies and other proteins for therapeutic applications. We believe that the unique capabilities of our patented technology give us an important advantage in the development of cost-effective commercial products in each of our target markets." About Dyadic Dyadic International, Inc., based in Jupiter, Florida, with operations in the United States of America, Hong Kong and mainland China, Poland and The Netherlands, is engaged in the development, manufacture and sale of biological products using a number of proprietary fungal strains to produce enzymes and other biomaterials, principally focused on a system for protein production based on the patented Chrysosporium lucknowense fungus, known as C1. Dyadic is applying its technologies to produce enzymes for use in converting various agricultural products (e.g. corn) and waste products (e.g. switch grass, wheat straw, sugar cane bagasse, etc.) into fermentable sugars, which can then be used in the production of traditional and cellulosic ethanol as well as other products currently derived from petroleum. Dyadic's C1 technology also is being developed to facilitate the discovery, development and large-scale production of human antibodies and other high-value therapeutic proteins. Dyadic currently sells more than 45 liquid and dry enzyme products to more than 200 industrial customers in approximately 50 countries for the textile, pulp & paper, animal feed, alcohol, starch, and food and beverage industries. Cautionary Statement for Forward-Looking Statements Certain statements contained in this press release are "forward-looking statements." These forward-looking statements involve risks and uncertainties that could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For a discussion of these risks and uncertainties, please see our filings from time to time with the Securities and Exchange Commission, which are available free of charge on the SEC's web site at http://www.sec.gov, including our Annual Report on Form 10-KSB for the year ended December 31, 2005, and our subsequent filings with the SEC. Except as required by law, we expressly disclaim any intent or obligation to update any forward-looking statements. Dyadic International, Inc. (AMEX:DIL), a biotechnology company, announced today that it was granted U.S. patent 7,122,330, "High-Throughput Screening of Expressed DNA Libraries in Filamentous Fungi," by the U.S. Patent and Trademark Office. Dr. Glenn Nedwin, Dyadic's Chief Scientific Officer, Executive Vice President and President of Dyadic's Biosciences Business, said, "This patent protects Dyadic's novel technology for robotic screening in filamentous fungi using our proprietary C1 Host Technology platform. With broad claims covering a number of other industrially relevant fungi, including Trichoderma and Aspergillus, we believe the patent also validates Dyadic's 'one stop shop' model where gene discovery and improvement, gene expression, and product manufacturing in quantities from 1 ml to 150,000 liters can all be performed in the same host organism. We believe that this, in turn, should improve the odds of identifying potentially useful proteins, shorten R&D development timelines, and reduce development costs." Dr. Nedwin added, "We already are using this patented technology in Dyadic's programs to identify optimal enzymes and enzyme mixtures to increase the efficiency of extracting sugars from renewable biomass, a critical step in the production of low-cost cellulosic ethanol, plastics, polymers and other products now derived from petroleum. We also are using our technology to expand the pipeline of new, more effective and lower cost enzymes used in the pulp & paper, textile, animal feed and other industrial processes, and are developing the technology to facilitate the rapid, low-cost screening of antibodies and other proteins for therapeutic applications. We believe that the unique capabilities of our patented technology give us an important advantage in the development of cost-effective commercial products in each of our target markets." About Dyadic Dyadic International, Inc., based in Jupiter, Florida, with operations in the United States of America, Hong Kong and mainland China, Poland and The Netherlands, is engaged in the development, manufacture and sale of biological products using a number of proprietary fungal strains to produce enzymes and other biomaterials, principally focused on a system for protein production based on the patented Chrysosporium lucknowense fungus, known as C1. Dyadic is applying its technologies to produce enzymes for use in converting various agricultural products (e.g. corn) and waste products (e.g. switch grass, wheat straw, sugar cane bagasse, etc.) into fermentable sugars, which can then be used in the production of traditional and cellulosic ethanol as well as other products currently derived from petroleum. Dyadic's C1 technology also is being developed to facilitate the discovery, development and large-scale production of human antibodies and other high-value therapeutic proteins. Dyadic currently sells more than 45 liquid and dry enzyme products to more than 200 industrial customers in approximately 50 countries for the textile, pulp & paper, animal feed, alcohol, starch, and food and beverage industries. Cautionary Statement for Forward-Looking Statements Certain statements contained in this press release are "forward-looking statements." These forward-looking statements involve risks and uncertainties that could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For a discussion of these risks and uncertainties, please see our filings from time to time with the Securities and Exchange Commission, which are available free of charge on the SEC's web site at http://www.sec.gov, including our Annual Report on Form 10-KSB for the year ended December 31, 2005, and our subsequent filings with the SEC. Except as required by law, we expressly disclaim any intent or obligation to update any forward-looking statements.